Sule Emmanuel A, Ewemade Festus
Dept. of Surgery, Delta state university, Abraka, Nigeria.
Dept. of Obstetrics and Gynaecology, University of Benin Teaching hospital, Nigeria.
Int J Surg Case Rep. 2015;17:117-20. doi: 10.1016/j.ijscr.2015.10.008. Epub 2015 Nov 4.
Although breast cancer is a common cancer, Pregnancy associated breast cancer is uncommon. Adjuvant chemotherapy administered intrapartum has been resolved to be safe from the second trimester.
To review cases of pregnancy associated breast cancer managed with adjuvant intrapartum chemotherapy.
Gravid patients diagnosed with breast cancer had chemotherapy administered by a slow infusion protocol at 3 weekly interval from the second trimester till 4 weeks to expected date of delivery. Obstetric scans were done to monitor fetal growth and development. Requisite surgery was carried out intrapartum and postpartum.
There were three cases of pregnancy associated breast cancer Age range 32-33 years, mean 32.5 years. Two cases presented in the second trimester while one presented in the third trimester. The second case had overt metastatic disease and was grave in respiratory distress. Histology showed invasive lobular carcinoma in two cases and extensive intraductal carcinoma with invasive component in the third. Immunohistochemistry showed triple negative in the first case and hormone positive in the third case. Wide local excision was done for a 3cm lump in the first case and mastectomy postpartum in the third case. but had no surgery. Doxorubicin and cyclophosphamide was administered three weekly from the second trimester up to 32 weeks and continued postpartum. Taxanes was administered afterwards. The grave clinical state of the second case was markedly improved with the first cycle of chemotherapy instituted. All cases had spontaneous vaginal delivery with good apgar scores. Children had normal developmental milestones. First case with breast conservation is clinically disease free, the second case demised postpartum from disease progression while the third had a mastectomy and is on cue for radiotherapy.
Adjuvant intrapartum chemotherapy had a successful outcome with birth of normal babies with normal developmental milestones in our miniseries.
尽管乳腺癌是一种常见癌症,但妊娠相关乳腺癌并不常见。已确定在孕中期后进行的产时辅助化疗是安全的。
回顾采用产时辅助化疗治疗的妊娠相关乳腺癌病例。
诊断为乳腺癌的孕妇在孕中期至预计分娩日期前4周,按照缓慢输注方案每3周进行一次化疗。进行产科超声检查以监测胎儿生长发育。在产时和产后进行必要的手术。
有3例妊娠相关乳腺癌病例,年龄范围为32 - 33岁,平均32.5岁。2例在孕中期就诊,1例在孕晚期就诊。第二例有明显的转移性疾病,且有严重的呼吸窘迫。组织学检查显示,2例为浸润性小叶癌,第三例为广泛导管内癌伴浸润成分。免疫组化显示,第一例为三阴性,第三例为激素阳性。第一例对一个3cm的肿块进行了广泛局部切除,第三例产后进行了乳房切除术,而第二例未进行手术。从孕中期到32周每3周给予多柔比星和环磷酰胺,并在产后继续使用。之后给予紫杉烷类药物。第二例患者在开始第一个化疗周期后,严重的临床状态有明显改善。所有病例均自然阴道分娩,阿氏评分良好。儿童发育里程碑正常。第一例保乳患者临床无疾病,第二例产后因疾病进展死亡,第三例进行了乳房切除术,正在等待放疗。
在我们的小系列研究中,产时辅助化疗取得了成功的结果,分娩出了发育里程碑正常的健康婴儿。